Dare Bioscience
DARE
About: Dare Bioscience Inc is a biopharmaceutical company committed to advancing products for women's health. The company identifies, develops, and brings to market a diverse portfolio of differentiated therapies that prioritize women's health and well-being, expand treatment options, and improve outcomes, in the areas of contraception, fertility, and vaginal and sexual health. The company's first product, XACIATO is a single-dose vaginal gel prescription product for the treatment of bacterial vaginosis in females 12 years of age and older. The company's portfolio includes two product candidates in clinical development namely, Ovaprene and Sildenafil Cream. It has one operating segment, women's health.
Employees: 23
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
0.71% more ownership
Funds ownership: 9.51% [Q1] → 10.22% (+0.71%) [Q2]
0% more funds holding
Funds holding: 24 [Q1] → 24 (+0) [Q2]
0% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 2
0% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 5
10% less capital invested
Capital invested by funds: $2.39M [Q1] → $2.16M (-$229K) [Q2]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
1 analyst rating
|
Maxim Group
Caroline Palomeque
|
$8
|
Buy
Upgraded
|
4 Sep 2025 |
Financial journalist opinion
